US stock market declines as Vaxcyte, Biohaven, and Moderna lead losses
US stocks closed sharply lower on March 31, 2025, led by biotech and tech losses. Learn why markets are reacting to tariffs, interest rates, and ... Read More
Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant ... Read More
Apellis to submit NDA for intravitreal pegcetacoplan to FDA in H1 2022
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal pegcetacoplan to the US Food and Drug ... Read More
Positive results for pegcetacoplan in C3 glomerulopathy treatment: A step forward in kidney disease research
Apellis Pharmaceuticals has unveiled significant findings from its Phase 2 DISCOVERY clinical trial, offering a ray of hope for patients suffering from C3 glomerulopathy (C3G), ... Read More